Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00002454
Status:
UNKNOWN
Last Update Posted:
2011-07-26
First Post:
1999-11-01
Brief Title:
Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx
Sponsor:
University of Medicine and Dentistry of New Jersey
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx
Status:
UNKNOWN
Status Verified Date:
2002-01
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Vaccines made from papilloma virus cells may make the body build an immune response to and kill papilloma cells
PURPOSE Phase II trial to study the effectiveness of papilloma virus vaccine in treating young patients with recurrent papilloma of the larynx
PURPOSE Phase II trial to study the effectiveness of papilloma virus vaccine in treating young patients with recurrent papilloma of the larynx
Detailed Description:
OBJECTIVES I Determine the immune response in patients with juvenile papilloma of the larynx treated with autogenous vaccine derived from each patients own tumor
OUTLINE Patients receive autogenous papilloma vaccine intradermally and subcutaneously weekly for 20 weeks
PROJECTED ACCRUAL Not specified
OUTLINE Patients receive autogenous papilloma vaccine intradermally and subcutaneously weekly for 20 weeks
PROJECTED ACCRUAL Not specified
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NJ-M-41-1976 | None | None | None |
| NJ-LAR-1 | None | None | None |